From November 11, 2023 to December 31, 2023, the company has repurchased 751,500 shares, representing 0.19% for CNY 10.25 million. With this, the company has completed the repurchase of 751,500 shares, representing 0.19% for CNY 10.25 million under the buyback announced on November 16, 2023.
Shanghai Labway Clinical Laboratory Co., Ltd
Equities
301060
CNE100004RG8
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.03 CNY | +2.66% | +0.91% | -24.53% |
May. 30 | Labway Clinical Laboratory Names Chief Financial Officer | MT |
Apr. 26 | Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-24.53% | 554M | |
-24.16% | 7.76B | |
+68.65% | 4.33B | |
-2.98% | 2.64B | |
+2.72% | 2.63B | |
-46.17% | 2.16B | |
-22.12% | 1.46B | |
+13.62% | 1.17B | |
-43.81% | 1.14B | |
+20.41% | 999M |
- Stock Market
- Equities
- 301060 Stock
- News Shanghai Labway Clinical Laboratory Co., Ltd
- Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.